Straits Times Index
3,301.91 +8.98 (+0.27%) Nikkei
38,236.07 -38.03 (-0.10%) Hang Seng
18,540.86 +64.94 (+0.35%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,353.88 +949.81 (+1.50%) CMC Crypto 200
1,373.22 +60.59 (+4.62%)
Dr. Reddy's Laboratories Limited (DRREDDY.BO)
| Previous close | 6,349.95 |
| Open | 6,410.35 |
| Bid | 6,293.15 x 0 |
| Ask | 6,297.55 x 0 |
| Day's range | 6,265.00 - 6,410.35 |
| 52-week range | 4,383.40 - 6,505.50 |
| Volume | |
| Avg. volume | 13,510 |
| Market cap | 1.049T |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 20.12 |
| EPS (TTM) | 313.05 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | 40.00 (0.63%) |
| Ex-dividend date | 11 Jul 2023 |
| 1y target est | 2,581.68 |
Business WireDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
